Fosaprepitant
- Generic Name
- Fosaprepitant
- Brand Names
- Emend, Focinvez, Ivemend
- Drug Type
- Small Molecule
- Chemical Formula
- C23H22F7N4O6P
- CAS Number
- 172673-20-0
- Unique Ingredient Identifier
- 6L8OF9XRDC
- Background
Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment.
- Indication
Fosaprepitant is indicated in adult and pediatric patients ≥6 months of age, in combination with other antiemetic agents, for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, including high-dose cisplatin. It is also indicated for the treatment of delayed nausea and v...
- Associated Conditions
- Acute Chemotherapy-Induced Nausea and Vomiting (CINV) caused by highly emetogenic chemotherapy, Delayed Chemotherapy-Induced Nausea and Vomiting (CINV) caused by highly emetogenic chemotherapy, Delayed Chemotherapy-Induced Nausea and Vomiting (CINV) caused by moderately emetogenic chemotherapy
- Associated Therapies
- -
Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and Metoclopramide
- Conditions
- Interventions
- First Posted Date
- 2024-12-18
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Montefiore Medical Center
- Target Recruit Count
- 212
- Registration Number
- NCT06740812
- Locations
- 🇺🇸
Montefiore Medical Center, Bronx, New York, United States
Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2023-05-03
- Target Recruit Count
- 1028
- Registration Number
- NCT05841849
- Locations
- 🇨🇳
the Second Affiliated Hospital of Zhejiang Univercity School of Medicine, Hanzhou, Zhejiang, China
Triple Therapy of Dexamethasone, Palonosetron, and Fosaprepitant as PONV Prevention
- Conditions
- Interventions
- First Posted Date
- 2023-03-17
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 144
- Registration Number
- NCT05773950
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Shantou University Medical College
- Target Recruit Count
- 116
- Registration Number
- NCT05564286
- Locations
- 🇨🇳
Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China
Efficacy and Safety of Fosaprepitant in Preventing Chemotherapy-induced Vomiting in Children Treated With Medium and High Emetic Chemotherapeutic Drugs
- Conditions
- Interventions
- First Posted Date
- 2022-02-09
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Shanghai Children's Medical Center
- Target Recruit Count
- 120
- Registration Number
- NCT05230654
- Locations
- 🇨🇳
Shanghai Children's Medical Center, Shanghai, China
Granisetron Transdermal Patch for Prophylaxis of Delayed CINV
- First Posted Date
- 2021-06-03
- Last Posted Date
- 2021-06-03
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 140
- Registration Number
- NCT04912271
Comparative Study of Fosaprepitant and Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Caner Patients
- Conditions
- Interventions
- First Posted Date
- 2021-05-05
- Last Posted Date
- 2021-05-10
- Lead Sponsor
- Shanghai Children's Medical Center
- Target Recruit Count
- 120
- Registration Number
- NCT04873284
- Locations
- 🇨🇳
Shanghai Children's Medical Center, Shanghai, China
Fosaprepitant for the Prevention of Nausea and Emesis During Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma
- First Posted Date
- 2020-11-19
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 100
- Registration Number
- NCT04636632
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
PALONOSETRON X FOSAPREPITANT IN PONV
- Conditions
- Interventions
- First Posted Date
- 2018-07-16
- Last Posted Date
- 2019-03-12
- Lead Sponsor
- Hospital Federal de Bonsucesso
- Target Recruit Count
- 100
- Registration Number
- NCT03586817
- Locations
- 🇧🇷
Hospital Federal de Bonsucesso, Rio de Janeiro, Brazil
Importance of Substance P in Intracranial Pressure Elevation Following Traumatic Brain Injury
- First Posted Date
- 2017-01-30
- Last Posted Date
- 2022-11-03
- Lead Sponsor
- Arun Gupta
- Registration Number
- NCT03035838
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.